Revolutionary Israeli COVID Treatment Gets Approval for Advanced Trial –

0
10
Revolutionary Israeli COVID Treatment Gets Approval for Advanced Trial – fr


Coronavirus treatment touted by Prime Minister Benjamin Netanyahu as a ‘wonder drug’ earlier this year was approved by the Health Ministry for a Phase II / III trial, according to the hospital in which it was developed .

Professor Nadir Arber of Tel Aviv Sourasky Medical Center said Jerusalem post that its EXO-CD24 COVID-19 treatment will soon launch a double-blind placebo trial in which around 150 patients in moderate or severe condition will be treated with the drug.

Because the level of COVID-19 in Israel is extremely low, Sourasky will partner with other medical centers across the country, Arber said, and will likely expand the trial to other countries.

Georgia, for example, which has reported between 500 and 1,000 new cases daily according to the Worldometer site, has agreed to carry out a trial, once it receives authorization from the European Medicines Agency.

Additionally, Arber – and a spokesperson for Sourasky who confirmed the report – said the hospital was in dialogue with India, Brazil, Portugal, Costa Rica and the Czech Republic to seek approval. to also carry out tests there.

“I was in Georgia last week and they are very excited to do it,” Arber told the Poster.

Additionally, the treatment is being tested in Greece in what is called a dosing study to determine how much is needed to most effectively treat COVID-19.

EXO-CD24 was first mentioned in February, when Sourasky said 29 out of 30 (96%) of COVID-19 patients treated with it recovered within days and were discharged from hospital. Five more patients later received EXO-CD24 and had the same results.

Six patients received a higher dose than the others.

Around the same time, Netanyahu brought in Greek Prime Minister Kyriakos Mitsotakis to meet with Arber during his visit to Israel and learn more about the treatment. During a press conference with the Greek leader, Netanyahu held up a vial of Arber’s treatment and called it a “wonder drug.”

EXO-CD24 COVID-19 is based on exosomes enriched with CD24 and is intended to fight the cytokine storm, which overwhelms the immune system. Exosomes are responsible for cell-to-cell communication. In this case, they deliver the CD24 protein to the lungs, which helps calm the immune system.

A cytokine storm occurs when the body’s immune system overdrives and attacks itself – one of the leading causes of death in patients with COVID-19. Arber said a cytokine storm develops in between 5% and 7% of patients with COVID-19 within five to seven days.

How long will the trial last?

According to Arber, the goal is only a few months.

“It should only take a few months” to complete these tests, he told the Poster. “We have a very motivated staff and a great project that is very promising, secure and has the potential to make a real difference.”

Although Israel is largely out of the coronavirus crisis – and June 1 will lift all remaining health ministry restrictions except for indoor masks and those that apply to the Ben-Gurion Airport – There were between 400,000 and 800,000 new daily cases around the world last week.

LEAVE A REPLY

Please enter your comment!
Please enter your name here